April 2, 2021

Office of the Attorney General
State of Vermont

via email to: AGO.highcostprescriptiondrugs@vermont.gov

Pursuant to 18 V.S.A.§4637(c), Biogen is hereby providing additional information related to the notice of the introduction of a new prescription drug in the commercial market as submitted on March 3, 2021:

National Drug Code (NDC)	Description	Date Commercially Available	Wholesale Acquisition Cost (WAC)*
64406-0017-01	Plegridy Intramuscular, 125 mcg/0.5 mL for intramuscular administration in a single-dose prefilled syringe	03/01/2021	$7,205.54

*Price to wholesalers, without regard to prompt pay or other discounts, rebates, chargebacks, or any fees paid to wholesalers for services performed. Does not represent prices charged to other customers or classes of trade.

Additional information:

Requested Information	Biogen Submission
A description of the marketing and pricing plans used in the launch of the new drug in the United States and Internationally	Plegridy Intramuscular will be marketed to Healthcare Professionals, Patients, Payers, and other appropriate audiences for use in patients with Relapsing Forms of Multiple Sclerosis. Biogen has a set of Pricing Principles that inform pricing decisions for its products. Those principles are: 1. Value to Patients 2. Present and Future Benefit to Society 3. Fulfilling our commitment to Innovation 4. Evolution toward Value Based Care 5. Affordability & Sustainability *Further information on the Pricing Principles can be found at:* https://www.biogen.com/content/dam/corporate/en_us/pdfs/BIOGEN_PricingPrinciplesInfographic_4-26-19.pdf
The estimated volume of patients who may be prescribed the drug	As of the time of this submission, Biogen is unable to estimate the volume of patients who will be prescribed PLEGRIDY Intramuscular.

Requested Information	Biogen Submission
Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval	Plegridy Intramuscular was not granted breakthrough therapy designation or priority review.
The date and price of acquisition if the drug was not developed by the manufacturer	N/A

Please let me know if you need any additional information.

Thank You,

Chris Cheney
Associate Director, Contracts & Pricing Governance
Biogen | 133 Boston Post Road, 17-308 | Weston, MA | 02493
Email: chris.cheney@biogen.com | Direct: 781 464 5876